Get the Stockscreener App
60.40
0.83%
0.495
Celcuity Inc stock is traded at $60.40, with a volume of 984.04K.
It is up +0.83% in the last 24 hours and down -26.97% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$59.90
Open:
$60.67
24h Volume:
984.04K
Relative Volume:
0.55
Market Cap:
$2.96B
Revenue:
Net Income/Loss:
$-192.89M
P/E Ratio:
-15.50
EPS:
-3.8976
Net Cash Flow:
$-172.97M
1W Performance:
-11.01%
1M Performance:
-26.97%
6M Performance:
-51.09%
1Y Performance:
+20.72%
1-Day Range:
$60.00
$61.73
1-Week Range:
$58.98
$68.53
52-Week Range:
$45.03
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
60.40 | 2.96B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 128.88B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.59 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.61 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-26 | Initiated | JP Morgan | Overweight |
| May-04-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
New Strong Sell Stocks for October 14th - Zacks Investment Research
Celcuity Appoints David Gryska To Its Board Of Directors - The Manila Times
Why Celcuity Stock Was a Winner on Wednesday - The Motley Fool
Celcuity (NasdaqCM:CELC) Stock Forecast & Analyst Predictions - Simply Wall Street
Celcuity Inc.Common Stock (NQ: CELC - The Chronicle-Journal
Trading Systems Reacting to (CELC) Volatility - Stock Traders Daily
Transcript : Celcuity Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Celcuity at citigroup’s biopharma back to school summit: launch begins By Investing.com - Investing.com India
Celcuity at citigroup’s biopharma back to school summit: launch begins By Investing.com - Investing.com Canada
Celcuity (CELC) Institutional Ownership 2026 $CELC - MarketBeat
Celcuity at Wells Fargo healthcare conference: launch, data in focus By Investing.com - Investing.com Canada
Celcuity at Wells Fargo healthcare conference: launch, data in focus By Investing.com - Investing.com UK
Celcuity (CELC) Could Be 40% Undervalued After REVTORPYK FDA Filing - simplywall.st
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
Celcuity To Participate in Upcoming Investor Conferences - Yahoo Finance
How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer - simplywall.st
What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer? - simplywall.st
Celcuity (CELC): Landmark Approval Collides With A Costly Launch - Yahoo Finance
Celcuity submits application for breast cancer drug expansion - Investing.com
Celcuity’s three-drug breast cancer treatment cut progression or death risk 50% vs. alpelisib - Stock Titan
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer - Yahoo Finance
Celcuity Inc (CELC) Stock News Today - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call Transcript - AOL.com
Celcuity (CELC) Quarter in Focus: EPS Comes in Below Forecast in the Current Update; Closing Move: Shares Move 2.79% Down in the Available RecordEarnings Weakness Phase - vinanet.vn
E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ: CELC) insider updates stock holdings - Stock Titan
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating, Cuts Target Price to $173 - Moomoo
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp - MarketBeat
Celcuity awaits FDA review for second factory to launch cancer drug - Endpoints News
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Nigeria
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Australia
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com India
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com UK
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com India
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
Getting To A First Product Approval With Celcuity's Brian Sullivan｜Business Of Biotech - finance.biggo.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com South Africa
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com India
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - The National Law Review
Brian Sullivan: The $20 Million Bet That Resurrected Pfizer's Shelved Cancer Drug - finance.biggo.com
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Yahoo Finance
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celcuity Inc Stock (CELC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Former 10% owner |
Jul 14 '26 |
Sale |
102.50 |
3,100,000 |
317,750,000 |
442,940 |
| 667, L.P. | Former Affiliate |
Jul 14 '26 |
Proposed Sale |
102.50 |
261,368 |
26,790,220 |
0 |
| Baker Brothers Life Sciences, | Former Affiliate |
Jul 14 '26 |
Proposed Sale |
102.50 |
2,838,632 |
290,959,780 |
0 |
| Laing Lance G. | Chief Science Officer |
Jun 02 '26 |
Option Exercise |
9.89 |
1,000 |
9,890 |
1,251,000 |
| Buller Richard E | Director |
May 04 '26 |
Proposed Sale |
140.46 |
6,000 |
842,788 |
0 |
| Buller Richard E | Director |
May 04 '26 |
Sale |
140.46 |
9,000 |
1,264,181 |
6,760 |
| Dalvey David | Director |
May 04 '26 |
Sale |
140.68 |
25,000 |
3,517,000 |
65,000 |
| Buller Richard E | Director |
May 04 '26 |
Option Exercise |
5.10 |
9,000 |
45,900 |
15,760 |
| Dalvey David | Director |
May 04 '26 |
Proposed Sale |
140.68 |
25,000 |
3,517,000 |
0 |
| Buller Richard E | Director |
Mar 31 '26 |
Proposed Sale |
110.27 |
6,000 |
661,607 |
0 |
2.80%
2.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):